Loading stock data…
Taysha Gene Therapies (TSHA)
$6.73+0.39 (+6.15%)
Market ClosedLast close Jun 29
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Taysha Gene Therapies, Inc. in the Healthcare sector is trading at $6.73 with a market capitalization of $1.6B. Wall Street consensus targets $12.85 (13 analysts), implying a +90.9% move over the next 12 months. The stock is currently near its 52-week high of $7.30, remaining 34.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +90.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $5.49M | $0↓ | $1.99M↓ | $2.30M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$43.49M↓ | -$28.30M↑ | -$34.02M↓ | -$26.75M↓ | -$21.42M |
| Net Income | -$42.41M↓ | -$27.85M↑ | -$32.73M↓ | -$26.88M↓ | -$21.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company prima...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.28%
Volume
Today's trading volume
5.36M
Recent News
Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)
Taysha Gene Therapies Inc (NASDAQ:TSHA) shares rose 3. 6% in premarket trading on Monday after the company announced the completion of patient dosing in its pivotal Rett syndrome study and released updated long-term clinical data for its lead gene therapy candidate, TSHA-102.
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery
What Taysha Gene Therapies Stock Offers Investors Right Now Taysha Gene Therapies (TSHA) sits firmly in clinical-stage territory, working on adeno-associated virus-based gene therapies for severe central nervous system diseases, with programs spanning Rett syndrome, giant axonal neuropathy, and several rare pediatric conditions. With a market cap of about US$1.6b and reported revenue of US$7.471 million against a net loss of US$129.876 million, the stock presents a high-risk, research-focused...
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?
Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TSHA. Taysha Gene Therapies, Inc.’s share was trading at $5.36 as of June 9th. Taysha Therapeutics (TSHA) is a clinical-stage genetic medicine company focused on […]
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best small cap stocks to buy for 10x potential. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced financial results for fiscal Q1 2026 on May 6, reporting that it reaffirmed U.S. Food and Drug Administration (FDA) alignment on the planned pathway to a Biologics License Application (BLA) submission […]
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best US Stocks Under $5 to Buy. On May 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) with a price target of $17 on the stock. This update comes after the company reported results for the first quarter of 2026. Taysha […]